RBC Capital lowered the firm’s price target on Morphic to $76 from $80 but keeps an Outperform rating on the shares. The company’s Q3 update was “largely incremental” with execution seen as a focus in the quarter, the analyst tells investors in a research note. Morphic also continues in data generation mode with eyes on the randomized EMERALD-2 data expected in the first half of 2025 to strengthen MORF-057’s validation in IBD, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MORF:
- Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2023
- Morphic expects cash to fund operations through second half of 2027
- Morphic reports Q3 EPS (73c), consensus (95c)
- Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
- Biotech Alert: Searches spiking for these stocks today
